Thryv Therapeutics
Latest round
- Series B
Last raised
- Nov 2026
Total raised
- $49M
Investors
- 12
About Thryv Therapeutics
Based in Montreal, Canada and founded in 2019, Thryv Therapeutics Inc. develops medicines for to treat long QT syndrome, heart failure, and atrial fibrillation with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase.
Who invested in Thryv Therapeutics
12 investors across 2 rounds
See all investors in Thryv Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Thryv Therapeutics
Who invested in Thryv Therapeutics?
Thryv Therapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Thryv Therapeutics raised?
Thryv Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Thryv Therapeutics last raise money?
Thryv Therapeutics's most recent round on record is a Series B, in Nov 2026.
What does Thryv Therapeutics do?
Based in Montreal, Canada and founded in 2019, Thryv Therapeutics Inc.
Where is Thryv Therapeutics headquartered?
Thryv Therapeutics is headquartered in Montreal, Canada.
Which VCs invest in companies like Thryv Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Thryv Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Thryv Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.